Biovail Comments On Filing Of Lawsuit

Main Category: Medical Malpractice / Litigation
Also Included In: Pharma Industry / Biotech Industry
Article Date: 12 Oct 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Biovail Corporation (NYSE, TSX: BVF) today announced that it has been notified that a proposed securities class action lawsuit has been filed in the U.S. District Court Southern District of New York against the Company, its Chairman and two former officers. The complaint has been filed on behalf of all persons and entities that purchased Biovail securities from December 14, 2006 through July 19, 2007.

The complaint relates to statements alleged to have been made by the Company and by certain officers in respect of Aplenzin™ (bupropion hydrobromide tablets) during the product's U.S. regulatory approval process.

Biovail believes the claim is completely without merit and will defend itself vigorously.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products. The Company is focused on the development and commercialization of medicines that address unmet medical needs in niche specialty central nervous system (CNS) markets.

Biovail Corporation